Role of CCL20/CCR6/IL-17 in Non-Small Cell Lung Cancer
Author Information
Author(s): Kirshberg Sophie, Izhar Uzi, Amir Gail, Demma Jonathan, Vernea Fiona, Beider Katia, Shlomai Zippora, Wald Hanna, Zamir Gideon, Shapira Oz M., Peled Amnon, Wald Ori
Primary Institution: Hadassah University Hospital, Jerusalem, Israel
Hypothesis
The study aims to characterize the role of the CCL20/CCR6/IL-17 axis in NSCLC tumor growth.
Conclusion
The CCL20/CCR6 axis promotes NSCLC disease progression, with CCR6 identified as a potential prognostic marker.
Supporting Evidence
- CCL20 was highly expressed in 77.5% of tumor samples.
- High CCR6 expression was associated with a shorter disease-free survival.
- High CCR6 expression conferred a 4.87-fold increased risk for disease recurrence.
Takeaway
This study found that a specific signaling pathway in lung cancer helps tumors grow and could be a target for new treatments.
Methodology
The study involved assessing CCL20/CCR6 expression in tissue samples from NSCLC patients and correlating it with disease progression.
Limitations
The study has a relatively small sample size of 49 patients.
Participant Demographics
The study included 49 NSCLC patients, with a mean age of 65.8 years, comprising 25 females and 24 males.
Statistical Information
P-Value
0.0076
Confidence Interval
95% CI 1.52–15.563
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website